BIOA and BIOAB@SS Related Headlines
Go Back- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
- Bulletin from the Annual General Meeting in BioArctic AB (publ)
- FDA extends Leqembi Iqlik review period to August 24
- FDA extends Leqembi Iqlik review period to August 24
- Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.
- BioArctic publishes the Annual Report and Sustainability Report for 2025
- Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
- Leqembi included in China's commercial insurance innovative drug list
- Leqembi® approved for IV maintenance treatment in the United Kingdom
- Health Canada Grants Authorization for Leqembi® (lecanemab)
- Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
- Leqembi® approved for IV maintenance treatment in China
BIOA and BIOAB@SS Related Press Releases
Go Back- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
- Bulletin from the Annual General Meeting in BioArctic AB (publ)
- Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.
- BioArctic publishes the Annual Report and Sustainability Report for 2025
- Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
- Leqembi included in China's commercial insurance innovative drug list
- Leqembi® approved for IV maintenance treatment in the United Kingdom
- Health Canada Grants Authorization for Leqembi® (lecanemab)
- Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
- Leqembi® approved for IV maintenance treatment in China
